Memorial Sloan Kettering Cancer Center

Eli Lilly's experimental breast cancer drug, imlunestrant, met its main goal in a Phase 3 study, showing improved progression-free survival in HER2-negative, ER-positive patients. Combined with Verezenio, it offered longer survival and progression-free benefits. Imlunestrant, a next-gen SERD, aims to overcome resistance, particularly from ESR1 mutations. The trial enrolled 874 patients, with imlunestrant plus Verezenio reducing progression or death risk by 43% compared to imlunestrant alone. Side effects were higher with the combination treatment.

Lilly's Imlunestrant, an oral SERD, significantly improved progression-free survival (PFS) as monotherapy and in combination with Verzenio in ER+, HER2- advanced breast cancer patients. Imlunestrant reduced PFS risk by 38% vs. standard of care endocrine therapy (SOC ET) in ESR1 mutation patients and by 43% with Verzenio. Results published in The New England Journal of Medicine and presented at SABCS.

Imlunestrant, an oral SERD, improved PFS in ER+/HER2- advanced breast cancer with ESR1 mutations vs SOC endocrine therapy in the EMBER-3 trial. Combination with abemaciclib improved PFS in the overall population. Median PFS was 5.5 months for imlunestrant monotherapy vs 3.8 months for SOC in ESR1-mutated patients, and 9.4 months for imlunestrant plus abemaciclib vs 5.5 months for imlunestrant alone in the overall population.

Carta Healthcare acquired Realyze Intelligence to expand AI platforms for faster data abstraction and clinical trial matching. Both platforms aim to reduce labor demands and improve insights in oncology and other specialty areas.

Imlunestrant, a next-gen oral SERD, significantly improved progression-free survival vs standard care in ESR1-mutated breast cancer patients. Imlunestrant plus abemaciclib improved progression-free survival in all patients regardless of ESR1-mutation status. Imlunestrant alone did not significantly improve progression-free survival in the overall population but showed favorable safety profiles.

Imlunestrant, a next-gen SERD, improved progression-free survival in ER+/HER2- advanced breast cancer, effective as monotherapy in ESR1-mutated cases and in combination with abemaciclib. The phase III EMBER-3 trial showed imlunestrant reduced progression risk by 38% in ESR1-mutated patients and by 43% when combined with abemaciclib, offering an all-oral therapy option.

A review in *Blood Cancer Discovery* outlines a major multiple myeloma research project that supported the FDA's decision to greenlight minimal residual disease (MRD) as a biomarker endpoint for accelerated drug approval, potentially cutting a decade off the drug development process. The research, led by C. Ola Landgren and Sean Devlin, found MRD-negative disease reasonably likely to predict clinical benefit, streamlining drug development and regulatory review for multiple myeloma.

SELLAS Life Sciences Group reached the 60-event threshold in its Phase 3 REGAL trial of galinpepimut-S (GPS) for AML, triggering an interim analysis by the Independent Data Monitoring Committee in January 2025. The analysis will assess GPS's efficacy, futility, and safety.

EPCORE NHL-2 trial results show epcoritamab combo achieved 100% ORR and 87% CR in high-risk DLBCL patients. EPCORE NHL-1 trial data demonstrates durable responses and safety of epcoritamab monotherapy in R/R DLBCL. Both analyses presented at ASH.